These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32973992)

  • 1. Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope
    Beck-Peccoz P; Höybye C; Murray RD; Simsek S; Zabransky M; Zouater H; Stalla G
    Ther Adv Endocrinol Metab; 2020; 11():2042018820943377. PubMed ID: 32973992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
    Beck-Peccoz P; Höybye C; Murray RD; Simsek S; Zabransky M; Zouater H; Stalla G
    BMC Endocr Disord; 2019 Dec; 19(1):138. PubMed ID: 31829160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
    Höybye C; Beck-Peccoz P; Murray RD; Simsek S; Stalla G; Strasburger CJ; Urosevic D; Zouater H; Johannsson G
    Pituitary; 2021 Aug; 24(4):622-629. PubMed ID: 33742320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of Omnitrope
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    Eur J Pediatr; 2022 Jun; 181(6):2367-2378. PubMed ID: 35275291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency.
    Beck-Peccoz P; Minuto F; Leal-Cerro A; Zabransky M; Stalla G
    Ther Adv Endocrinol Metab; 2012 Jun; 3(3):85-91. PubMed ID: 23148199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
    Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
    BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
    Arosio M; Arnaldi G; Gasco V; Giavoli C; Puxeddu E; Vettor R; Ambrosio MR; Gallinari P; Zouater H; Fedeli P; Ferone D
    J Endocrinol Invest; 2021 Feb; 44(2):327-337. PubMed ID: 32507990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
    Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
    Pfäffle R; Schwab KO; Marginean O; Walczak M; Szalecki M; Schuck E; Zabransky M; Zucchini S
    Ther Adv Endocrinol Metab; 2013 Feb; 4(1):3-11. PubMed ID: 23515245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of Omnitrope
    Ferone D; Profka E; Gasco V; Ambrosio MR; Colao A; Di Somma C; Puxeddu E; Arnaldi G; Pagano C; Zecchi E; Pietropoli A; Beck-Peccoz P
    J Endocrinol Invest; 2017 Jun; 40(6):669-678. PubMed ID: 28161880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope
    Backeljauw P; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    J Pediatr Endocrinol Metab; 2021 Apr; 34(4):431-440. PubMed ID: 33647196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L; Antoniazzi F; Giavoli C; Bona G; Aversa T; Greggio NA; Guazzarotti L; Minelli R; Perrone L; Persani L; Pozzobon G; Ragusa L; Stagi S; Tornese G; Zecchino C; Gallinari P; Zouater H; Fedeli P; Zucchini S
    J Endocrinol Invest; 2021 Mar; 44(3):493-503. PubMed ID: 32557273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Pfäffle RW; Höybye C; Lundberg E; Battelino T; Kriström B; Giemza T; Zouater H
    Horm Res Paediatr; 2021; 94(3-4):133-143. PubMed ID: 34350858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
    Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
    Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
    [No Abstract]   [Full Text] [Related]  

  • 17. Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope
    Coutant R; Dupuis C; Pigeon P; Rebaud P
    Ther Adv Endocrinol Metab; 2017 Sep; 8(9):129-137. PubMed ID: 29051812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N; Saenger P; Wu YL; Woehling H; Frankel M; Lifshitz F; Muenzberg M; Rapaport R
    Biol Ther; 2014 Dec; 4(1-2):27-39. PubMed ID: 25096555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP; Walczak M; Birkholz-Walerzak D; Szalecki M; Nanu M; Woehling H; Schuck E
    Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.